279 related articles for article (PubMed ID: 36941643)
61. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
62. Outcomes of freehand interstitial brachytherapy in advanced gynecologic malignancies.
Bajwa HK; Singareddy R; Krishnam Raju A
Brachytherapy; 2020; 19(5):669-673. PubMed ID: 32466952
[TBL] [Abstract][Full Text] [Related]
63. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).
Yoshida K; Jastaniyah N; Sturdza A; Lindegaard J; Segedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz I; Haie-Meder C; Sasaki R; Pötter R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):788-96. PubMed ID: 26530747
[TBL] [Abstract][Full Text] [Related]
64. Single-Institution Experience in 3D MRI-Based Brachytherapy for Cervical Cancer for 239 Women: Can Dose Overcome Poor Response?
Horne ZD; Karukonda P; Kalash R; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Bochmeier MM; Berger JL; Taylor SE; Sukumvanich P; Beriwal S
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):157-164. PubMed ID: 30605752
[TBL] [Abstract][Full Text] [Related]
65. Education and training for image-guided adaptive brachytherapy for cervix cancer-The (GEC)-ESTRO/EMBRACE perspective.
Tan LT; Tanderup K; Kirisits C; Mahantshetty U; Swamidas J; Jürgenliemk-Schulz I; Lindegaard J; de Leeuw A; Nesvacil N; Assenholt M; Berger D; Diendorfer T; Dimopoulos J; Duke S; Ecker S; Fokdal L; Hellebust T; Jensen N; Kirchheiner K; Nout R; Petric P; Schmid M; Seppenwoolde Y; Sturdza A; Van Limbergen E; Haie-Meder C; Pötter R
Brachytherapy; 2020; 19(6):827-836. PubMed ID: 32811761
[TBL] [Abstract][Full Text] [Related]
66. Intensity modulated proton beam radiation for brachytherapy in patients with cervical carcinoma.
Clivio A; Kluge A; Cozzi L; Köhler C; Neumann O; Vanetti E; Wlodarczyk W; Marnitz S
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):897-903. PubMed ID: 24119834
[TBL] [Abstract][Full Text] [Related]
67. Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer.
Fokdal L; Ørtoft G; Hansen ES; Røhl L; Pedersen EM; Tanderup K; Lindegaard JC
Brachytherapy; 2014; 13(6):554-61. PubMed ID: 25056640
[TBL] [Abstract][Full Text] [Related]
68. Safety and Efficacy of 2D Brachytherapy vs. 3D Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer-A Single Institution Retrospective Study.
Faye MD; Petruccelli Araujo M; Wissing MD; Alrabiah K; Gilbert L; Zeng X; Souhami L; Alfieri J
Curr Oncol; 2023 May; 30(5):4966-4978. PubMed ID: 37232833
[TBL] [Abstract][Full Text] [Related]
69. Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy.
Serban M; Kirisits C; Pötter R; de Leeuw A; Nkiwane K; Dumas I; Nesvacil N; Swamidas J; Hudej R; Lowe G; Hellebust TP; Menon G; Oinam A; Bownes P; Oosterveld B; De Brabandere M; Koedooder K; Marthinsen ABL; Lindegaard J; Tanderup K;
Radiother Oncol; 2018 Dec; 129(3):567-574. PubMed ID: 30243671
[TBL] [Abstract][Full Text] [Related]
70. 45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims?
Mazeron R; Petit C; Rivin E; Limkin E; Dumas I; Maroun P; Annede P; Martinetti F; Seisen T; Lefkopoulos D; Chargari C; Haie-Meder C
Clin Oncol (R Coll Radiol); 2016 Mar; 28(3):171-7. PubMed ID: 26547694
[TBL] [Abstract][Full Text] [Related]
71. Transrectal ultrasound for image-guided adaptive brachytherapy in cervix cancer - An alternative to MRI for target definition?
Schmid MP; Nesvacil N; Pötter R; Kronreif G; Kirisits C
Radiother Oncol; 2016 Sep; 120(3):467-472. PubMed ID: 26921168
[TBL] [Abstract][Full Text] [Related]
72. Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for Cervical Cancer.
Simpson DR; Scanderbeg DJ; Carmona R; McMurtrie RM; Einck J; Mell LK; McHale MT; Saenz CC; Plaxe SC; Harrison T; Mundt AJ; Yashar CM
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):150-7. PubMed ID: 26130230
[TBL] [Abstract][Full Text] [Related]
73. Intra-fractional dosimetric analysis of image-guided intracavitary brachytherapy of cervical cancer.
Yan J; Zhu J; Chen K; Yu L; Zhang F
Radiat Oncol; 2021 Aug; 16(1):144. PubMed ID: 34348758
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008.
Majercakova K; Pötter R; Kirisits C; Banerjee S; Sturdza AE; Georg P; Nesvacil N; Schmid MP
Acta Oncol; 2015; 54(9):1551-7. PubMed ID: 26198658
[TBL] [Abstract][Full Text] [Related]
75. Dose to the non-involved uterine corpus with MRI guided brachytherapy in locally advanced cervical cancer.
Sapru S; Mohamed S; Fokdal L; Nkiwane K; Swamidas J; Mahantshetty U; Kirisits C; Pötter R; Christian Lindegaard J; Tanderup K
Radiother Oncol; 2013 Apr; 107(1):93-8. PubMed ID: 23490270
[TBL] [Abstract][Full Text] [Related]
76. Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis.
Spampinato S; Fokdal LU; Pötter R; Haie-Meder C; Lindegaard JC; Schmid MP; Sturdza A; Jürgenliemk-Schulz IM; Mahantshetty U; Segedin B; Bruheim K; Hoskin P; Rai B; Huang F; Cooper R; van der Steen-Banasik E; Van Limbergen E; Sundset M; Westerveld H; Nout RA; Jensen NBK; Kirisits C; Kirchheiner K; Tanderup K;
Radiother Oncol; 2021 May; 158():300-308. PubMed ID: 33065183
[TBL] [Abstract][Full Text] [Related]
77. Dosimetric comparison of
Shukla AK; Jangid PK; Rajpurohit VS; Verma A; Dangayach SK; Gagrani V; Rathore NK
J Cancer Res Ther; 2019; 15(6):1212-1215. PubMed ID: 31898649
[TBL] [Abstract][Full Text] [Related]
78. Safe dose escalation and reduction of the fraction number of uterine cervical brachytherapy using a gel spacer in the rectovaginal and vesicouterine septum: A planning study.
Takatsu J; Murakami N; Muramoto Y; Karino T; Oshima M; Kosugi Y; Kawamoto T; Terao Y; Shikama N
Brachytherapy; 2024; 23(2):115-122. PubMed ID: 38040605
[TBL] [Abstract][Full Text] [Related]
79. Targeting the GTV in medically inoperable endometrial cancer using brachytherapy.
Merfeld EC; Kuczmarska-Haas A; Burr AR; Witt JS; Francis DM; Ntambi JN; Desai VK; Huang JY; Miller JR; Lawless MJ; Wallace CR; Anderson BM; Bradley KA
Brachytherapy; 2022; 21(6):792-798. PubMed ID: 36030167
[TBL] [Abstract][Full Text] [Related]
80. Early clinical outcome of coverage probability based treatment planning for simultaneous integrated boost of nodes in locally advanced cervical cancer.
Lindegaard JC; Assenholt M; Ramlov A; Fokdal LU; Alber M; Tanderup K
Acta Oncol; 2017 Nov; 56(11):1479-1486. PubMed ID: 28849684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
